格隆汇10月24日丨昊海生物科技(06826.HK)公布2025年第三季度报告。营业收入约为人民币5.95亿元， 同比下降11.29%。归属于上市公司股东的净利润为9358.21万元，同比下降11.39%。基本每股收益为 0.40元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海昊海生物科技股份有限公司 主席 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2025年第三季度報告 本公告乃上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則第13.09(2)及13.10B條以及香港 法例第571章證券及期貨條例第XIVA部刊發，旨在向本公司股東及公眾人士提供 本公司最新的財務資料。 茲載列本公司同時在上海證券交易所網站發佈的、截至2025年9月30日止三個月 及九個月之本集團未經審計業績（「第三季度報告」）。第三季度報告所載財務數據 乃根據中國企業會計準則編製，且未經審計。以下所載第三季度報告以中英文版 本編製。有任何歧義，概以第三季度報告中文版本為準。 本 ...

Core Insights - Haohai Biological Technology (688366) reported a decline in revenue and net profit for the first three quarters of 2025, with revenue at 1.899 billion yuan, down 8.47% year-on-year, and net profit at 305 million yuan, down 10.63% year-on-year [1] Financial Performance - The company's revenue for the first three quarters was 1.899 billion yuan, reflecting an 8.47% decrease compared to the same period last year [1] - The net profit attributable to the company was 305 million yuan, which represents a 10.63% decline year-on-year [1] Factors Affecting Performance - The decline in sales revenue was attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [1]

Core Insights - Haohai Biological Technology (688366.SH) reported a total operating revenue of 1.899 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 8.47% [1] - The net profit attributable to shareholders of the parent company was 305 million yuan, down 10.63% year-on-year [1] - The basic earnings per share stood at 1.31 yuan [1]

Company Performance - Haohai Biological Technology reported Q3 performance with revenue of approximately 1.899 billion yuan, a year-on-year decrease of 8.47% [1] - The net profit attributable to shareholders was about 305 million yuan, down 10.63% year-on-year [1] - Basic earnings per share were 1.31 yuan, reflecting a decrease of 10.27% compared to the previous year [1] Market Context - As of the report, Haohai Biological Technology has a market capitalization of 11.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals totaling 80 billion US dollars this year [2] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising [2]

上海昊海生物科技股份有限公司 2025 年第三季度报告 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海昊海生物科技股份有限公司 2025 年第三季度报告 | 加权平均净资产收益率 | 1.66 | 减少 | 个 0.19 | 5.39 | 减少 0.54 | 个百 | | --- | --- | --- | --- | --- | --- | --- | | （%） | | | 百分点 | | | 分点 | | 研发投入合计 | 50,698,539.50 | | -19.19 | 149,099,493.94 | | -20.75 | | 研发投入占营业收入的 | 8.53 | 减少 | 0.83 个 | 7.85 | 减少 1.22 | 个百 | | 比例（%） | | | 百分点 | | | 分点 | | | 本报告期末 | | | 上年度末 | 本报告期末比 上年度末增减 | | | | | | ...

昊海生科公告，第三季度营收为5.95亿元，下降11.29%；净利润为9358.21万元，下降11.39%。前三季 度营收为18.99亿元，下降8.47%；净利润为3.05亿元，下降10.63%。 ...

Core Insights - The domestic medical beauty market in China is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][3][6] - Major players are expanding overseas as domestic profit margins shrink, indicating a strategic shift towards international markets [1][11] Market Competition - New Oxygen launched a low-priced "Miracle Youth Needle" at 2999 yuan, significantly undercutting competitors and causing dissatisfaction among upstream material suppliers [3][6] - Huaxi Biological and Juzi Biological are engaged in a fierce dispute over collagen product patents, highlighting the intense competition in the market [3][4] - The competition is characterized by a shift from regulatory competition to market-driven competition, with a growing number of brands entering the space [6][7] Financial Performance - Major companies like Aimeike and Huaxi Biological reported significant declines in revenue and net profit, with Aimeike's revenue and net profit down 21.59% and 29.57% respectively in the first half of the year [7][10] - Huaxi Biological's revenue and net profit also fell by 19.57% and 35.38% respectively, marking a continuous decline over two years [7][10] International Expansion - Chinese medical beauty companies are increasingly looking to international markets, with firms like Aimeike and Huaxi Biological investing in overseas partnerships [1][11] - The strategy involves acquiring or investing in foreign companies to introduce Chinese products to international markets, rather than relying on traditional business development methods [11][12] Emerging Markets - There is a growing opportunity in emerging markets such as Southeast Asia and Latin America, where demand for cost-effective and multifunctional products is rising [12][13] - Companies are focusing on building technological barriers and moving away from the "low-price" label by investing in advanced materials and techniques [13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會會議召開日期 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二 零二五年十月二十四日（星期五）舉行董事會會議，藉以（其中包括）審議及通過本 公司及其附屬公司截至二零二五年九月三十日止九個月之第三季度業績及其發佈。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，二零二五年十月十四日 * 僅供識別 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公 司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 ...

格隆汇10月14日丨昊海生物科技(06826.HK)发布公告，谨定于2025年10月24日(星期五)举行董事会会 议，藉以(其中包括)审议及通过本公司及其附属公司截至2025年9月30日止九个月的第三季度业绩及其 发布。 ...